ABSTRACT
The hydroxyproline/creatinine excretion ratios have been measured in half-hour fasting morning urine specimens from breast cancer patients and compared with corresponding values measured in 24 hour urine collections. Both parameters show a close correlation. The value of the half-hour test in predicting the presence of early bone metastases, in monitoring the response of patients to therapy and in eliminating unwanted effects of dietary Hydroxyproline intake are discussed.
Subject(s)
Breast Neoplasms/urine , Hydroxyproline/urine , Bone Neoplasms/diagnosis , Bone Neoplasms/urine , Creatine/urine , Female , Humans , Neoplasm Metastasis , Time FactorsABSTRACT
The urinary excretion of hydroxyproline, measured as the hydroxyproline: creatinine ratio, was useful in monitoring the progression of metastatic cancer of the breast. After new treatment was started changes in the hydroxyproline excretion occurred earlier than other clinically observable responses. The test could therefore be used for predicting the response to treatment and early detection of the sensitivity of the tumour to hormone therapy.
